Skip to main content

Drug Safety

      In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.
      Autoinflammatory/Still's Disease Panel - EULAR2020

      Drs. Olga Petryna, Petros Efthimiou, Apostolos Kontzias and Jack Cush discuss autoinflammatory highlights from the Virtual EULAR 2020 meeting June 3-6

      These were my top abstracts from Thursday, 4th of June at EULAR 2020:
      These were my top abstracts from Thursday, 4th of June at EULAR 2020:
      For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf.  Listed below are the top 5 studies and their summaries presented at the recent EULAR e-Congress conference streamed from Germany that I found impactful:
      Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.
      Here is my top-five from day one at EULAR:
      SELECT-Choice: UPA vs ABA in RA

      Dr. Jack Cush from EULAR2020 Virtual Conference

      OP0151

      Updated EULAR Recommendations for RA Management

      Dr. Kathryn Dao from EULAR2020 Virtual Conference

      GCA and Risk of Cancer or Visual Loss

      Dr. Olga Petryna from EULAR2020 Virtual Conference

      OP0149 Tocilizumab Treats Visual Loss in GCA

      OP0143 GCA in Israel and risk of Cancer

      Bimekizumab in Ankylosing Spondylitis

      Dr. Rachel Tate from EULAR2020 Virtual Conference

      Enticing New Options in ANCA-Associated Vasculitis

      Dr. David Liew from EULAR2020 ANCA-Associated Vasculitis Avacopan vs Prednisone MAINRITSAN 2 study - Calprotectin

      RT @DrPetryna: How do you approach your PsA patients with suboptimal response to MTX in moderate doses?

      Olga Petryna DrPetryna

      5 years ago
      How do you approach your PsA patients with suboptimal response to MTX in moderate doses?
      RT @DrPetryna: #EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outc

      Olga Petryna DrPetryna

      5 years ago
      #EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
      ×